Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Kalvista Pharmaceuticals's Sebetralstat?
Sebetralstat is a small molecule commercialized by Kalvista Pharmaceuticals, with a leading Pre-Registration program in Hereditary Angioedema (HAE) (C1 Esterase...
Sebetralstat by Kalvista Pharmaceuticals for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Sebetralstat is under clinical development by Kalvista Pharmaceuticals and currently in Pre-Registration for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH]...
Risk adjusted net present value: What is the current valuation of Kalvista Pharmaceuticals's Sebetralstat?
Sebetralstat is a small molecule commercialized by Kalvista Pharmaceuticals, with a leading Phase III program in Hereditary Angioedema (HAE) (C1...